Literature DB >> 18940390

High-sensitivity C-reactive protein and silent myocardial ischemia in Chinese with type 2 diabetes mellitus.

Ming-Chia Hsieh1, Kai-Jen Tien, Shun-Jen Chang, Daw-Shyong Perng, Jeng-Yueh Hsiao, Yu-Wen Chen, Yu-Hung Chang, Hsuan-Wen Kuo, Pi-Chen Lin.   

Abstract

Coronary artery disease (CAD) is a major cause of morbidity and mortality in patients with type 2 diabetes mellitus. When diabetes exists in patients with established CAD, absolute risk for future events is very high. Diabetic patients often have severe, yet asymptomatic, CAD. Although high-sensitivity C-reactive protein (hsCRP) is a strong independent risk factor for cardiovascular events, there is an unclear association between it and silent myocardial ischemia in diabetic patients. In this study, we assess the relationship between hsCRP and silent myocardial ischemia in Chinese with type 2 diabetes mellitus. We designed a cross-sectional study with 225 asymptomatic diabetic patients having no known CAD. Ischemia was assessed by myocardial perfusion imaging. A total of 109 patients (48.4%) was found to have silent myocardial ischemia. Logistic regression analysis revealed age (odds ratio = 4.01, P = .002) (95% confidence interval, 1.98-7.44) and hsCRP (odds ratio = 2.58, P = .005) (95% confidence interval, 1.33-5.01) to be associated with greater risk of silent myocardial ischemia. Using the American Diabetes Association screening guidelines to evaluate risk, we found silent myocardial ischemia to be equally distributed between diabetic patients with 2 or more cardiac risk factors and those with less than 2 risk factors. Twenty-seven (24.8%) patients with silent myocardial ischemia were missed when the American Diabetes Association guidelines were used alone. High-sensitivity C-reactive protein was associated with silent myocardial ischemia in our study. High-sensitivity C-reactive protein might help detect silent myocardial ischemia in diabetic Chinese who may need aggressive treatment to reduce future CAD morbidity and mortality in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940390     DOI: 10.1016/j.metabol.2008.06.007

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

Review 1.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Authors:  Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2014-08-15

2.  Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.

Authors:  Rachel G Miller; Tina Costacou; Trevor J Orchard
Journal:  Diab Vasc Dis Res       Date:  2009-10-28       Impact factor: 3.291

3.  Cardiovascular risk evaluation and prevalence of silent myocardial ischemia in subjects with asymptomatic carotid artery disease.

Authors:  Marco Matteo Ciccone; Artor Niccoli-Asabella; Pietro Scicchitano; Michele Gesualdo; Antonio Notaristefano; Domenico Chieppa; Santa Carbonara; Gabriella Ricci; Marco Sassara; Corinna Altini; Giovanni Quistelli; Mario Erminio Lepera; Stefano Favale; Giuseppe Rubini
Journal:  Vasc Health Risk Manag       Date:  2011-03-04

4.  Microalbuminuria predicts silent myocardial ischaemia in type 2 diabetes patients.

Authors:  Giampiero Giovacchini; Mario Cappagli; Stefano Carro; Sandro Borrini; Antonella Montepagani; Rossella Leoncini; Gianfranco Mazzotta; Gianmario Sambuceti; Giuliano Mariani; Duccio Volterrani; Michael J Zellweger; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-12       Impact factor: 9.236

5.  Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study.

Authors:  Dan Mo; Songfang Liu; Hong Ma; Haoming Tian; Honglin Yu; Xiangxun Zhang; Nanwei Tong; Jiayu Liao; Yan Ren
Journal:  Drug Des Devel Ther       Date:  2019-08-09       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.